Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Annals of Hematology
Literature
1.
Siegal DM, Garcia DA, Crowther MA (2014) How I treat target-specific oral anticoagulant-associated bleeding. Blood 123:1152–1158CrossRefPubMed
2.
Siegal DM, Curnutte JT, Connolly SJ et al (2015) Andexanet Alfa for the reversal of Factor Xa inhibitor activity. N Engl J Med 373:2413–2424CrossRefPubMed
3.
Levy JH, Ageno W, Chan NC et al (2016) When and how to use antidotes for the reversal of direct oral anticoagulants: guidance from the SSC of the ISTH. J Thromb Haemost 14:623–627CrossRefPubMed
4.
Ageno W, Buller HR, Falanga A et al (2016) Managing reversal of direct oral anticoagulants in emergency situations. Anticoagulation Education Task Force White Paper. Thromb Haemost. doi:10.​1160/​TH16-05-0363
5.
Linkins LA, Moffat K (2014) Monitoring the anticoagulant effect after a massive rivaroxaban overdose. J Thromb Haemost 12:1570–1571CrossRefPubMed
6.
Sajkov D, Gallus A (2015) Accidental rivaroxaban overdose in a patient with pulmonary embolism: some lessons for managing new oral anticoagulants. Clin Med Insights Case Rep 8:57–59CrossRefPubMedPubMedCentral
7.
Repplinger DJ, Hoffman RS, Nelson LS et al (2016) Lack of significant bleeding despite large acute rivaroxaban overdose confirmed with whole blood concentrations. Clin Toxicol 54:647–649CrossRef
8.
Spiller HA, Mowry JB, Aleguas A et al (2016) An observational study of the factor Xa inhibitors rivaroxaban and apixaban as reported to eight poison centers. Ann Emerg Med 67:189–195CrossRefPubMed
Metadata
Title
Attempted suicide with rivaroxaban
Authors
Dorit Blickstein
Saaid Younes
Sigal Nakav
Publication date
01-12-2016
Publisher
Springer Berlin Heidelberg
Published in
Annals of Hematology / Issue 12/2016
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-016-2816-6

Other articles of this Issue 12/2016

Annals of Hematology 12/2016 Go to the issue

Original Article

Clinical features and survival of extranodal natural killer/T cell lymphoma with and without hemophagocytic syndrome

Original Article

Incidence of catheter-related thrombosis in acute leukemia patients: a comparative, retrospective study of the safety of peripherally inserted vs. centrally inserted central venous catheters

Original Article

BCR and chemokine responses upon anti-IgM and anti-IgD stimulation in chronic lymphocytic leukaemia

Original Article

The impact of postpartum hemoglobin levels on maternal quality of life after delivery: a prospective exploratory study

Letter to the Editor

Effects of low-dose thalidomide in chronic refractory immune thrombocytopenia and contributions to the dispensation of glucocorticoid dependence

Original Article

CD34 expression and the outcome of nucleophosmin 1-mutated acute myeloid leukemia
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits